marimastat analogs (AstraZeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namemarimastat analogs (AstraZeneca)
Drug Alias Namemarimastat analogs (Zeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase inhibitorsDisintegrin and metalloproteinase domain-containing protein 17 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17Matrix metalloproteinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesZeneca Group Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZeneca Group PlcAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A